Anusorn Lungkaphin

Dr. Anusorn Lungkaphin

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
LTLaongdao Thongnak
Laongdao Thongnak
APAnchalee Pongchaidecha
Anchalee Pongchaidecha
Anusorn LungkaphinAnusorn Lungkaphin
Anusorn Lungkaphin

19 June 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
KJKrit Jaikumkao
Krit Jaikumkao
APAnchalee Pongchaidecha
Anchalee Pongchaidecha
NCNuttawud Chueakula
Nuttawud Chueakula
LTLa‐Ongdao Thongnak
La‐Ongdao Thongnak
KWKeerati Wanchai
Keerati Wanchai
Anusorn LungkaphinAnusorn Lungkaphin
Anusorn Lungkaphin

11 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KJKrit Jaikumkao
Krit Jaikumkao
APAnchalee Pongchaidecha
Anchalee Pongchaidecha
LTLa-Ongdao Thongnak
La-Ongdao Thongnak
KWKeerati Wanchai
Keerati Wanchai
PAPhatchawan Arjinajarn
Phatchawan Arjinajarn
Anusorn LungkaphinAnusorn Lungkaphin
Anusorn Lungkaphin
Gentamicin is a commonly used aminoglycoside antibiotic. However, its therapeutic use is limited by its nephrotoxicity. The mechanisms of gentamicin-induced nephrotoxicity are principally from renal inflammation and oxidative stress. Since atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, exerts lipid-lowering effects, antioxidant, anti-inflammatory as well as anti-apoptotic effects, this study aimed to investigate the protective effects of atorvastatin against gentamicin-induced nephrotoxicity. Male Sprague Dawley rats were used and nephrotoxicity was induced by intraperitoneal injection of gentamicin, 100 mg/kg/day, for 15 days. Atorvastatin, 10 mg/kg/day, was administered by orally gavage 30 min before gentamicin injection on day 1 to 15 (pretreatment) or on day 10 to15 (delayed treatment). For only atorvastatin treatment group, it was given on day 1 to 15. At the end of the experiment, kidney weight, blood urea nitrogen and serum creatinine as well as renal inflammation (NF-κB, TNFαR1, IL-6 and iNOS), renal fibrosis (TGFβ1), ER stress (calpain, GRP78, CHOP, and caspase 12) and apoptotic markers (cleaved caspase-3, Bax, and Bcl-2) as well as TUNEL assay were determined. Gentamicin-induced nephrotoxicity was confirmed by marked elevations in serum urea and creatinine, kidney hypertrophy, renal inflammation, fibrosis, ER stress and apoptosis and attenuation of creatinine clearance. Atorvastatin pre and delayed treatment significantly improved renal function and decreased renal NF-κB, TNFαR1, IL-6, iNOS and TGFβ1 expressions. They also attenuated calpain, GRP78, CHOP, caspase 12, Bax, and increased Bcl-2 expressions in gentamicin-treated rat. These results indicate that atorvastatin treatment could attenuate gentamicin-induced nephrotoxicity in rats, substantiated by the reduction of inflammation, ER stress and apoptosis. The effect of atorvastatin in protecting from renal damage induced by gentamicin seems to be more effective when it beginning given along with gentamicin or pretreatment.

1 August 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
PAPhatchawan Arjinajarn
Phatchawan Arjinajarn
NCNuttawud Chueakula
Nuttawud Chueakula
APAnchalee Pongchaidecha
Anchalee Pongchaidecha
KJKrit Jaikumkao
Krit Jaikumkao
VCVaranuj Chatsudthipong
Varanuj Chatsudthipong
Anusorn LungkaphinAnusorn Lungkaphin
Anusorn Lungkaphin

10 December 2019 in Clinical Science
Verified
Journal Article
Closed access
PDF file
MSMyat Theingi Swe
Myat Theingi Swe
LTLaongdao Thongnak
Laongdao Thongnak
KJKrit Jaikumkao
Krit Jaikumkao
APAnchalee Pongchaidecha
Anchalee Pongchaidecha
VCVaranuj Chatsudthipong
Varanuj Chatsudthipong
Anusorn LungkaphinAnusorn Lungkaphin
Anusorn Lungkaphin
Background: With an increasing prevalence of obesity and metabolic syndrome, exploring the effects and delineating the mechanisms of possible therapeutic agents are of critical importance. We examined the effects of SGLT2 inhibitor-dapagliflozin on insulin resistance, hepatic gluconeogenesis, hepatic injury and pancreatic ER stress in high-fat diet-induced obese rats. Materials and methods: Male Wistar rats were fed with normal diet (ND) or high-fat diet for 16 weeks. Then high-fat rats were given vehicle (HF) or dapagliflozin (1 mg/kg/day; HFDapa) or metformin (30 mg/kg/day; HFMet) for another 4 weeks. Results: We found that dapagliflozin ameliorated high-fat diet-induced insulin resistance. The fasting plasma glucose level was comparable among groups, although dapagliflozin treatment led to substantial glycosuria. Hepatic gluconeogenic enzymes, PEPCK, G6Pase and FBPase, expression was not different in HF rats compared with ND rats. Meanwhile, dapagliflozin-treated group exhibited the elevation of these enzymes in parallel with the rise of transcription factor CREB, co-factor PGC1α and upstream regulator SIRT1. Hepatic oxidative stress, inflammation and NAFLD activity score as well as hepatic and pancreatic ER stress and apoptosis in obese rats were attenuated by dapagliflozin. Conclusion: We conclude that dapagliflozin improved obesity-related insulin resistance, hepatic and pancreatic injury independent of fasting plasma glucose level. Of note, dapagliflozin-induced glycosuria apparently triggered the up-regulation of hepatic gluconeogenic enzymes to prevent hypoglycemia.

8 February 2021 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
KJKrit Jaikumkao
Krit Jaikumkao
SPSasivimon Promsan
Sasivimon Promsan
LTLaongdao Thongnak
Laongdao Thongnak
MSMyat T. Swe
Myat T. Swe
MTMonruedee Tapanya
Monruedee Tapanya
Anusorn LungkaphinAnusorn Lungkaphin
Anusorn Lungkaphin